US Bancorp’s NextCure NXTC Stock Holding History

US Bancorp’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-33	Closed	-$3K	–	4153
2021 Q2	$3K	Buy	33 +21	+175%	+$2.15K	﹤0.01%	3744
2021 Q1	$1K	Buy	12 +3	+33%	+$434	﹤0.01%	3808
2020 Q4	$1K	Buy	+9	New	+$1.16K	﹤0.01%	3686
2020 Q3	–	Sell	-4	Closed	-$1K	–	3806
2020 Q2	$1K	Buy	+4	New	+$1.52K	﹤0.01%	3633

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

US Bancorp's NXTC Position: Q3 2021 in Review

US Bancorp sold out of NextCure (NXTC) in Q3 2021, closing a stake of 33 shares — an estimated $3K sold.

US Bancorp first reported a position in NXTC in Q2 2020 and held it in 4 quarters. The position peaked at $3K in Q2 2021. 71 funds tracked by Wall St. Rank hold NXTC as of Q3 2021.

US Bancorp reported no remaining NextCure position as of Q3 2021 after selling out during the quarter.
US Bancorp sold 33 NextCure shares in Q3 2021, an estimated $3K.
US Bancorp first reported a position in NextCure in Q2 2020 and held it in 4 quarters.
US Bancorp's NextCure position peaked at $3K in Q2 2021.
71 funds tracked by Wall St. Rank held NextCure as of Q3 2021.

Based on US Bancorp's 13F filing for Q3 2021, filed 10 Nov 2021.